CompletedPhase 2NCT00582634

Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer

* To determine if docetaxel and cisplatin can be administered in a dose intense manner in the adjuvant setting in resected non-small cell lung cancer * To evaluate the time to progression and overall survival * To evaluate toxicities of this chemotherapy combination in the adjuvant setting * To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in patients treated with this regimen

Checked against the public recordLast updated Nov 19, 2019 · Source: ClinicalTrials.gov

StatusCompleted
PhasePhase 2
U.S. locations1
SponsorUniversity of Wisconsin, Madison
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
University of Wisconsin, Madison
Interventions being studied
Drug: docetaxel and cisplatin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Stage IB to IIIA non-small cell lung cancer completely resected within 4 to 8 weeks of initiating treatment on study * Performance Status ECOG 0 or 1 * Peripheral neuropathy: \< grade 1 * Adequate blood cell counts * Adequate liver and hepatic function * Women of childbearing potential must have a negative pregnancy test. * Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter Exclusion Criteria: * Patients with a history of severe hypersensitivity reaction to Docetaxel® or other drugs formulated with polysorbate 80. * Women who are breast-feeding. * Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin that has been treated curatively) * Uncontrolled cardiac disease or uncontrolled hypertension

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Wisconsin Comprehensive Cancer CenterMadison, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 19, 2019. Always confirm current availability with the study team.

View original record ↗